Pfizer secures ex-China rights to Starna in vivo CAR-T programmes

Pfizer has signed a multi-billion-dollar licensing agreement with Starna Therapeutics to acquire ex-China rights to three in vivo CAR-T programmes targeting autoimmune diseases. The deal, which was finalised in the same week that Pfizer chief executive Albert Bourla highlighted China’s expanding role in global pharmaceutical innovation, involves an upfront payment of $330m. Under the terms of the agreement, Starna is positioned to receive up to $2.3bn in additional development and commercial milestones, alongside royalties on net sales from any products that emerge from the partnership.

The pharmaceutical company confirmed that the three programmes are currently in the pre-IND phase, although it did not disclose further specifics regarding the individual candidates. Pfizer has secured the rights to utilise Starna’s proprietary in vivo CAR-T technology within the inflammation and immunology sectors, as well as in oncology. The agreement also grants Pfizer the exclusive ability to license compounds developed under a separate research collaboration. Additionally, the company has obtained an option to expand its territorial rights to include Greater China, should it choose to pursue that market in the future.

This strategic move aligns with a broader industry trend towards in vivo CAR-T therapies, which are viewed as more attractive than ex vivo alternatives due to the elimination of complex manufacturing processes and scalability hurdles. Pfizer has previously developed ex vivo CAR-T therapies through licensing agreements with Cellectis and Servier. The shift to in vivo candidates mirrors recent activity by other major players, including Eli Lilly, which acquired Orna Therapeutics for $2.4bn in February and Kelonia for $7bn in April. Johnson and Johnson and Moderna have also conducted deals targeting this modality this year.

Michael Vincent, Pfizer’s chief inflammation and immunology officer, stated that in vivo CAR-T represents an emerging and promising approach for treating autoimmune diseases, particularly for patients who do not respond adequately to current treatment options. He noted that Pfizer’s significant experience in developing and manufacturing RNA-based medicines globally, combined with Starna’s technology, provides a powerful method to pursue these therapeutic approaches. Bourla had previously suggested at the Jefferies Global Healthcare Conference in London that competition in the sector is evolving away from traditional Western big phama dominance, driven by China’s significant growth in recent years. However, the increasing focus on national security policies in the United States may curtail other types of cross-border transactions, even as traditional licensing deals continue to be conducted.

Post Disclaimer

The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.

This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.

The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.

Our Socials

Recent Posts

Stockmark.1T logo with computer monitor icon from Stockmark.it
Loading Next Post...
Loading

Signing-in 3 seconds...

Signing-up 3 seconds...